Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06032949 · ClinicalTrials.gov registry record · NA

Vialize Use for the Reduction of Vascular Groin Incisional Dehiscence and Infection

A NA study of Vascular Diseases, sponsored by University of Florida.

Completed
Registry status
NA
Development phase
50
Enrollment target
1
Study location

NCT06032949 is a NA study of Vascular Diseases that has completed, run by University of Florida. The registered enrollment target is 50 participants, below the 560-participant average among 40 other Vascular Diseases trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06032949, a NA study of Vascular Diseases, has completed, sponsored by University of Florida.

COMPLETED
Registry status
NA
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

Groin incisions in vascular surgery have complications in up to 30% of cases at 30 days, resulting in reductions in patient quality of life and increased costs. Prior attempts at reducing this complication rate have been largely unsuccessful. The purpose of this study is to determine the feasibility of routine Vialize use for vascular surgeries involving a groin incision and to determine the rates of surgical site infection/dehiscence in such patients receiving subcutaneous Vialize.

Conditions Studied

Interventions

  • OTHER Vialize

Study Locations (1)

Florida

  • UF Health Heart & Vascular Hospital - Gainesville

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2023-10-23
Est. Completion 2025-02-28
Phase NA

Sponsor

University of Florida

1,106 total trials

What the Registry Record Tells You About NCT06032949

The ClinicalTrials.gov registry entry for NCT06032949 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 560-participant average among 40 other Vascular Diseases trials with a reported enrollment target (91% lower). The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Vascular Diseases appearing as the primary indexed condition, and to 1 intervention - of which Vialize is the first listed.

NCT06032949 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT06032949 about?

NCT06032949 is a clinical study titled "Vialize Use for the Reduction of Vascular Groin Incisional Dehiscence and Infection". Groin incisions in vascular surgery have complications in up to 30% of cases at 30 days, resulting in reductions in patient quality of life and increased costs. Prior attempts at reducing this complication rate have been largely unsuccessful. The purpose of this study is to determine the feasibility...

What is the current status of trial NCT06032949?

This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2023-10-23. Estimated completion is 2025-02-28.

What conditions does trial NCT06032949 study?

This clinical trial studies the following conditions: Vascular Diseases.

What interventions are being tested in trial NCT06032949?

The interventions under investigation include: Vialize (OTHER).

Who is sponsoring clinical trial NCT06032949?

This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06032949 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Vascular Diseases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.